Mineralys Therapeutics, Inc. (MLYS)
- Previous Close
12.93 - Open
13.23 - Bid 12.83 x 200
- Ask 13.12 x 200
- Day's Range
12.89 - 13.23 - 52 Week Range
5.85 - 17.44 - Volume
14,814 - Avg. Volume
152,245 - Market Cap (intraday)
639.969M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.18 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.50
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
mineralystx.comRecent News: MLYS
Performance Overview: MLYS
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MLYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MLYS
Valuation Measures
Market Cap
641.96M
Enterprise Value
645.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-7.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.09%
Return on Equity (ttm)
-29.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-90.8M
Diluted EPS (ttm)
-2.18
Balance Sheet and Cash Flow
Total Cash (mrq)
338.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-54.2M
Research Analysis: MLYS
Company Insights: MLYS
MLYS does not have Company Insights